 "Molnupiravir")
Amid safety concerns around Merck’s anti-viral drug Molnupiravir, the American pharma giant came out in defense of its drug developed in collaboration with Ridgeback Biotherapeutics.
In a statement, MSD (Merck is known as MSD outside the US and Canada) said, “We are confident in the clinical profile of Molnupiravir, which demonstrated a significant reduction in the risk of hospitalisation or death in our phase-3 clinical trial with no observed safety concerns when compared to the placebo group.”
The company claimed that the drug interrupts replication of the Sars-CoV-2 virus for variants like Delta, Gamma, and Mu.
The statement further said,
